+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07455383

Evaluating the Efficacy and Safety of ALKS 2680 Tablets Compared to Placebo in Adults With Narcolepsy Type 1

Led by Alkermes, Inc. · Updated on 2026-10-07

150

Participants Needed

44

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ALKS 2680 tablets in adults with Narcolepsy Type 1 NT1 to measure reductions in daytime sleepiness, sudden muscle tone loss cataplexy, and overall disease symptoms. This phase 3 clinical trial compares the effects of ALKS 2680 with placebo tablets to assess their impact on these key aspects of NT1. Participants are randomly assigned to one of three groups a placebo group or one of two different dose groups of ALKS 2680 tablets. All participants take their assigned oral tablets daily for 12 weeks. The study uses a triple-blind design, meaning that participants, investigators, and others involved do not know which treatment is being given. During the 12-week treatment, participants will be monitored for changes in sleep latency using the Maintenance of Wakefulness Test, daytime sleepiness via the Epworth Sleepiness Scale, weekly cataplexy rates, and other cognitive and fatigue assessments. Safety is tracked through the incidence of treatment-emergent adverse events up to 14 weeks. Outcome measures also include patient global impressions and narcolepsy severity scales to evaluate overall disease impact.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Research Team

D

Director, Clinical Trial Manager

D

Director, Clinical Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here